Crossmark

Market-driven, value-based, advance commitment (MVAC): accelerating the development of a pathbreaking universal drug regimen to end TB

Crossref DOI link: https://doi.org/10.1136/bmjgh-2019-002061

Published Online: 2020-04-23

Published Print: 2020-04

Update policy: https://doi.org/10.1136/crossmarkpolicy

Authors

Chalkidou, Kalipso

Towse, Adrian

Silverman, Rachel

Garau, Martina

Ramakrishnan, Ganesh
Funding

Funding for this research was provided by:

Bill and Melinda Gates Foundation (OPP1191987)
License Information

License valid from 2020-04-23